Opaleye Management Inc. 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-09 4:05 pm Sale | 2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 0 0.000% | -2,810,000 (Position Closed) | Filing |
| 2023-04-12 4:15 pm Purchase | 2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 2,810,000 5.390% | 2,810,000 (New Position) | Filing |